Breast cancer patient access to social work

2016 ◽  
Vol 17 (5) ◽  
pp. 531-543
Author(s):  
Yuko K Abbott
Keyword(s):  
Breast Cancer ◽  
Social Work ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Clinical Area ◽  
Oncology Social Work ◽  
The Impact ◽  
Office Location

Summary This study was conducted to understand the impact of oncology social work office location on breast cancer patients’ access and utilization of social work services. It also explored the current status of oncology social work offices and the perceptions among Association of Oncology Social Work Listserv members. The frequency and types of interventions and referral time were determined retrospectively. Association of Oncology Social Work Listserv members were surveyed. Findings From 461 new breast cancer patient charts, 52 were referred to social work during study period. Face-to-face interventions decreased by 0.8 contact ( p = .0221) and telephone interventions increased by 1.8 contacts ( p = .0293) after social work office was relocated away from clinical area. Referral time to social work services decreased unexpectedly by 14.5 days ( p = .076) after office relocation. Association of Oncology Social Work Listserv survey results identify an office location as possible barrier, though most respondents have a private office in clinical area, accessible to patients. Survey finding is limited due to low response rate. Applications There are many challenges to ensuring timey and effective delivery of social work services to breast cancer patients. Social Ecological framework is used to understand the impacts of office location on access to social work services. Study results suggest that office relocation has had mix impacts on patients. Raising awareness of social worker services among patients early in cancer trajectory is needed for patient empowerment and to ensure access to social work services. Further research is needed to understand barriers, identify effective strategies in order to guide and improve clinical practice.

scholarly journals Literature Review: Social Determinant of Health in Breast Cancer Patients Survival

2021 ◽  
Vol 9 (E) ◽  
pp. 624-628
Author(s):  
Azriful Azriful ◽  
Fatmawaty Mallapiang ◽  
Yessy Kurniati
Keyword(s):  
Breast Cancer ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Cancer Patients ◽  
Social Determinants ◽  
Health Determinants ◽  
Free Text ◽  
Breast Cancer Patients ◽  
Access To Health Services ◽  
Medical Subject Headings

BACKGROUND: Social determinants have an important role in the survival of breast cancer patients. AIM: This article aims to reviews the social determinants that affect the survival of breast cancer patient. METHODS: We searched PubMed and Google Scholar for identifying studies related to this review using free-text terms and Medical Subject Headings terms. Both experimental and observational studies on social determinants of breast cancer patient survival which were published in the English language have been included in this review except expert opinions, commentaries, editorials, and review articles. Ten studies were eligible to be included in review. RESULTS: Social health determinants that play a role in the survival of breast cancer patients are education level, place of residence, socioeconomic status, social environment, racial discrimination, and access to health services. CONCLUSION: Social determinants have an influence on the survival of breast cancer patients, so it is important to pay attention to these factors.

scholarly journals Literature Review: Teknik Relaksasi untuk Penerimaan Diri Pasien Kanker Payudara

2019 ◽  
Vol 10 (2) ◽  
pp. 298
Author(s):  
Ni Made Merlin ◽  
Anggorowati Anggorowati ◽  
Chandra Bagus Ropyanto ◽  
Antonius Rino Vanchapo
Keyword(s):  
Breast Cancer ◽  
Literature Review ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Cancer Patients ◽  
Relaxation Technique ◽  
Evidence Based ◽  
Relaxation Techniques ◽  
Breast Cancer Patients ◽  
Self Acceptance

<p>Breast cancer patients experience low self-acceptance and some of the experiencing psychological problems but not a lot of research to increasing self-acceptance. Additional intervention is needed to improve the effectiveness to increase self-acceptance. Technique relaxation is especially related because easy and quick to learn, it involves no risk, does not need use or purchased equipment and can be used on its own and immediately to tiredness and ill patients. This paper offers a literature review assessing the implications of previous studies order to create evidence-based decisions about the possibility to use of relaxation techniques with adult breast cancer patient for low self-acceptance. The Science Direct, EBSCOhost, Pubmed, DOAJ, Google Scholar database were searched in 2017 in orders to replied two questions: are relaxation technique effective to increase self-acceptance in breast cancer patients, and implications the previous investigation to future research concerning increase self-acceptance in breast cancer patients? Four articles included in the literature review. The relaxation technique for breast cancer patients with low self-acceptance is statically significant, and good evidence-based to practice. Some use of relaxation techniques in this study needs clarification as to whether it can be used directly or need to learn. Procedures in the collection of data in the articles also need to be assessed. In this literature review explain 4 relaxation technique to use for increasing self-acceptance in breast cancer, there are self-forgiveness, meditation, tai-chi, reflection, prayer, mindfulness. This literature review can be used as the basis for the decision to use relaxation techniques for increasing self-acceptance in the breast cancer patient.</p>

scholarly journals Possible Association of Typhoon Hagibis and the COVID-19 Pandemic on Patient Delay in Breast Cancer Patients: a case report

2021 ◽  
Author(s):  
Yudai Kaneda ◽  
Akihiko Ozaki ◽  
Masahiro Wada ◽  
Tomohiro Kurokawa ◽  
Toyoaki Sawano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Patient Care ◽  
Cancer Patients ◽  
Initial Presentation ◽  
Breast Cancer Patients ◽  
Cancer Management ◽  
Breast Cancer Management

Little is known on how disasters interact in their impacts on patient care. We experienced a breast cancer patient whose initial presentation was delayed for two years due to the COVID-19 pandemic and Typhoon Hagibis. Increasing awareness is needed on the combined impacts of disasters on breast cancer management.

scholarly journals High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2907
Author(s):  
Maral Jamshidi ◽  
Rainer Fagerholm ◽  
Taru A. Muranen ◽  
Sippy Kaur ◽  
Swapnil Potdar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Pathway Analysis ◽  
Patient Survival ◽  
Breast Cancer Cell Lines ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Cancer Pathogenesis ◽  
The Impact

Deregulated miRNA expression has been suggested in several stages of breast cancer pathogenesis. We have studied the miR-30 family, in particular miR-30d, in relation to breast cancer patient survival and treatment outcomes. With tumor specimens from 1238 breast cancer patients, we analyzed the association of miR-30d expression with tumor characteristics with the 5-year occurrence of breast cancer-specific death or distant metastasis (BDDM), and with 10-year breast cancer survival (BCS). We conducted a two-stage drug-screen to investigate the impact of miR-30 family members (miR-30a-30e) on sensitivity to doxorubicin and lapatinib in six breast cancer cell lines HCC1937, HCC1954, MDA-MB-361, MCF7, MDA-MB-436 and CAL-120, using drug sensitivity scores (DSS) to compare the miR-30 family mimics to their specific inhibitors. The study was complemented with Ingenuity Pathway Analysis (IPA) with the METABRIC data. We found that while high miR-30d expression is typical for aggressive tumors, it predicts better metastasis-free (pBDDM = 0.035, HR = 0.63, 95% CI = 0.4–0.9) and breast cancer-specific survival (pBCS = 0.018, HR = 0.61, 95% CI = 0.4–0.9), especially in HER2-positive (pBDDM = 0.0009), ER-negative (pBDDM = 0.003), p53-positive (pBDDM = 0.011), and highly proliferating (pBDDM = 0.0004) subgroups, and after adjuvant chemotherapy (pBDDM = 0.035). MiR-30d predicted survival independently of standard prognostic markers (pBDDM = 0.0004). In the drug-screening test, the miR-30 family sensitized the HER2-positive HCC1954 cell line to lapatinib (p < 10–2) and HCC1937, MDA-MB-361, MDA-MB-436 and CAL120 to doxorubicin (p < 10–4) with an opposite impact on MCF7. According to the pathway analysis, the miR-30 family has a suppressive effect on cell motility and metastasis in breast cancer. Our results suggest prognostic and predictive potential for the miR-30 family, which warrants further investigation.

scholarly journals Solitary Bone Metastasis beneath the Shoulder Shield: Coincidence or Cause?

2006 ◽  
Vol 13 (4) ◽  
pp. 121-123
Author(s):  
G. Fan ◽  
E. Sinclair ◽  
M. Christakis ◽  
L. Erhlich ◽  
J. Zubovits ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Cancer Patients ◽  
Locoregional Control ◽  
Breast Cancer Patients ◽  
Solitary Bone Metastasis

Post-mastectomy radiotherapy has been demonstrated to improve locoregional control in breast cancer patients. We report a case involving a 44-year-old breast cancer patient who presented with a solitary bone metastasis in the area beneath the shoulder shield, likely from a coincidental recurrence.

scholarly journals The chromatin remodeler SMARCD3 regulates cell cycle progression and its expression predicts survival outcome in ER+ breast cancer

2019 ◽  
Author(s):  
Romain Tropée ◽  
Bárbara de la Peña Avalos ◽  
Madeline Gough ◽  
Cameron Snell ◽  
Pascal H.G. Duijf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Cancer Patients ◽  
Chromatin Remodeling ◽  
Survival Rates ◽  
Transcriptional Networks ◽  
Breast Cancer Patients ◽  
Chromatin Remodelers

AbstractChromatin remodeling plays an essential role in regulating transcriptional networks and timing of gene expression. Chromatin remodelers such as SWItch/Sucrose Non-Fermentable (SWI/SNF) harbor many protein components, with the catalytic subunit providing ATPase activity to displace histones along or from the DNA molecules, and associated subunits ensuring tissue specificity and transcriptional or co-transcriptional activities. Mutations in several of the SWI/SNF subunits have been linked to cancer. Here, we describe how SMARCD3/Baf60c expression is associated with hormone positive (ER+) breast cancer. The level SMARCD3, as detected by immunohistochemistry in breast cancer patient samples, is correlated with differential long-term disease-free survival. In contrast, the expression level of SMARCD1/Baf60a and SMARCD2/Baf60b, which are mutually exclusive within the SWI/SNF complex and have a partially redundant function, lacks predictive value in breast cancer patient samples. Lower proliferation rates are observed in SMARCD3 depleted cells, which reflects a failure to fully progress through G2/M, and an increase in endoreplication. In the absence of SMARCD3, p21 accumulates in cells but does not halt the cell cycle, and DNA damage accumulates and remains unrepaired. Taken together, our data begin to explain why ER+ breast cancer patients with low SMARCD3 expressing tumors exhibit reduced survival rates compared to patients expressing normal or higher levels of SMARCD3. SMARCD3 might act as a tumor suppressor role through regulation of cell cycle checkpoints and could be a reliable and specific breast cancer prognostic biomarker.SignificanceMutations in chromatin remodelers are a leading cause of cancer. Estrogen Receptor positive (ER+) breast cancers represent approximately 80% of all cases diagnosed. Although these tumors can be treated with hormone therapy, most breast cancer fatalities occur in ER+ breast cancer patients, due to metastasis. Low expression of SMARCD3 in ER+ cancer is associated with diminished survival rates. As such, SMARCD3 could be used as a predictive biomarker for survival. In addition, we have identified a role for SMARCD3 in the cell cycle, which could at least partially explain its protective role in breast cancer. While catalytic subunits are often viewed as the major components in chromatin remodeling function, we show here new evidence that mutations or silencing of SMARCD3 may also contribute to genomic instability and thus development of breast cancer.

PSYCHOLOGICAL REHABILITATION AND SCREENING OF EMOTIONAL STRESS IN CANCER PATIENTS

2017 ◽  
Vol 63 (2) ◽  
pp. 316-319 ◽  
Author(s):  
Valentina Chulkova ◽  
Tatyana Semiglazova ◽  
Margarita Vagaytseva ◽  
Andrey Karitskiy ◽  
Yevgeniy Demin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patient ◽  
Cancer Patients ◽  
Emotional Stress ◽  
Self Esteem ◽  
Breast Cancer Patients ◽  
Psychological Study ◽  
Psychological Assistance

Psychological rehabilitation is an integral part of rehabilitation of a cancer patient. Psychological rehabilitation is aimed at a patient adaptation in the situation of the disease and improvement his quality of life. Understanding of an oncological disease is extreme and (or) crisis situation and monitoring dynamics of the psychological statement of a patient allows using differentiated approach in the provision of professional psychological assistance. The modified scale of self-esteem level of distress (IPOS) was used for screening of mental and emotional stress of cancer patients. There were selected groups of cancer patients who were most in need of professional psychological assistance. Results of a psychological study of one of these groups - breast cancer patients - are presented.

scholarly journals CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Jennifer K. Lang ◽  
Badri Karthikeyan ◽  
Adolfo Quiñones-Lombraña ◽  
Rachael Hageman Blair ◽  
Amy P. Early ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Care Center ◽  
Left Ventricular ◽  
The Body ◽  
Left Ventricular Ejection ◽  
Breast Cancer Patients ◽  
Ventricular Ejection Fraction ◽  
Echocardiographic Parameters ◽  
The Impact

Abstract Background The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact of CBR3 V244M on the risk for anthracycline-related cardiotoxicity in adult cohorts. Objectives This study evaluated the presence of associations between CBR3 V244M genotype status and changes in echocardiographic parameters in breast cancer patients undergoing doxorubicin treatment. Methods We recruited 155 patients with breast cancer receiving treatment with doxorubicin (DOX) at Roswell Park Comprehensive Care Center (Buffalo, NY) to a prospective single arm observational pharmacogenetic study. Patients were genotyped for the CBR3 V244M variant. 92 patients received an echocardiogram at baseline (t0 month) and at 6 months (t6 months) of follow up after DOX treatment. Apical two-chamber and four-chamber echocardiographic images were used to calculate volumes and left ventricular ejection fraction (LVEF) using Simpson’s biplane rule by investigators blinded to all patient data. Volumetric indices were evaluated by normalizing the cardiac volumes to the body surface area (BSA). Results Breast cancer patients with CBR3 GG and AG genotypes both experienced a statistically significant reduction in LVEF at 6 months following initiation of DOX treatment for breast cancer compared with their pre-DOX baseline study. Patients homozygous for the CBR3 V244M G allele (CBR3 V244) exhibited a further statistically significant decrease in LVEF at 6 months following DOX therapy in comparison with patients with heterozygous AG genotype. We found no differences in age, pre-existing cardiac diseases associated with myocardial injury, cumulative DOX dose, or concurrent use of cardioprotective medication between CBR3 genotype groups. Conclusions CBR3 V244M genotype status is associated with changes in echocardiographic parameters suggestive of early anthracycline-related cardiomyopathy in subjects undergoing chemotherapy for breast cancer.

Sign in / Sign up

Export Citation Format

Share Document